Pfizer's Cardura Approved For BPH
Pfizer has received approval from the US Food and Drug Administration to market its selective alpha adrenoceptor blocking drug Cardura (doxazosin mesylate) for the treatment of benign prostatic hyperplasia. The product has been marketed in the USA since 1991 as an antihypertensive agent.
The USA is the fifth country to approve Cardura for BPH, after Austria, Colombia, the Netherlands and Slovakia. Applications are pending in 20 other countries, according to Pfizer. In the USA, Cardura will be marketed by both the Roerig sales force of Pfizer's US Pharmaceuticals Group and American Medical Systems, a division of Pfizer's Hospital Products Group.
BPH is an area of increasing interest, with products such as Merck & Co's Proscar (finasteride) and Abbott's Hytrin (terazosin) jostling for market share. Pfizer now has an opportunity to increase Cardura sales in a fairly large market; around seven million American men are thought to suffer from the condition, but of these only 6% seek treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze